Leukaemia - chronic myeloid leukaemia

The PBS subsidises ponatinib for patients with chronic myeloid leukaemia.

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ponatinib under the National Health Act 1953, section 85 for patients with chronic myeloid leukaemia (CML).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ponatinib.

Authority Applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for first continuing authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

All written applications must include the completed:

After we approve the first continuing application for ponatinib treatment, subsequent continuing applications can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 July 2022